Nicole Verdun, a highly respected individual in the cell and gene therapy space, was placed on administrative leave this week ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Wolfe Research ...

The reported dismissal of high-ranking CBER officials Nicole Verdun and Rachael Anatol resurfaced lingering concerns about ...

The stock market rose within a mini-range for the week amid Israel-Iran headlines and the Federal Reserve's rate outlook.

The latest shake-up at the FDA forced out the top two officials in charge of reviewing cell and gene therapies, analysts said.

AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.